AstraZeneca exec joins Palatin
Executive Summary
Former AstraZeneca VP Biologics Global R&D Trevor Hallam joins Palatin as exec VP-R&D. Palatin's lead R&D product is the melanocortin agonist PT-141, which is in Phase II studies for erectile dysfunction. Palatin is developing PT-141 with King Pharmaceuticals...